Dyadic International receives a funding award from CEPI

Dyadic International (DYAI) announced that it has received a funding award from CEPI to use C1 to accelerate the development of protein-based vaccines. CEPI is providing $4.5M to non-profit Fondazione Biotecnopolo di Siena for proof-of-concept research that will explore whether producing antigens in C1 filamentous fungus-applying technology owned by Dyadic-is a faster and cost-effective alternative to the more established route of producing antigens in mammalian cells.